为了确定全身扩散加权磁共振成像 (WB-DWI/MRI) 对预测复发性上皮性卵巢癌次级细胞减灭手术可切除疾病的诊断价值，首次复发的上皮性卵巢癌患者和铂药无效间隔时间至少为6个月的患者于2012年1月至2021年12月期间在一个三级转诊医院进行了一项回顾性队列研究。纳入标准为：（a）首次复发的上皮性卵巢癌；（b）铂药无效间隔时间≥6个月；（c）拟进行次级细胞减灭手术并取得完全的肉眼切除；以及（d）进行了WB-DWI/MRI检查。计算了WB-DWI/MRI对预测次级细胞减灭手术过程中完全切除的诊断性测试，以及WB-DWI/MRI显示可切除疾病与不可切除疾病的患者的无进展生存期和总生存期。共鉴定了238名患者，其中123名（51.7%）进行了次级细胞减灭手术。WB-DWI/MRI对判断可切除疾病的敏感性为93.6% （95% CI 87.3%到96.9%），特异性为93.0% （95% CI 87.3%到96.3%），准确性为93.3% （95% CI 89.3%到96.1%）。阳性预测值为91.9% （95% CI 85.3%到95.7%）。WB-DWI/MRI对可切除疾病的预测与改善无进展生存期（中位数19个月vs 9个月；无进展风险比 [HR] 0.36；95% CI 0.26到0.50）和总生存期（中位数75个月vs 28个月；死亡风险比 [HR] 0.33；95% CI 0.23到0.47）相关。WB-DWI/MRI能够准确预测在次级细胞减灭手术时铂药无效间隔时间≥6个月的患者可切除疾病，并且可能成为目前使用的模型的有价值的补充。© IGCS and ESGO 2023。不得进行商业再利用。请参阅权利和权限。由BMJ出版。

To determine the diagnostic value of whole-body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) to predict resectable disease at the time of secondary cytoreductive surgery for relapsed epithelial ovarian cancer with a platinum-free interval of at least 6 months.A retrospective cohort study between January 2012 and December 2021 in a tertiary referral hospital. Inclusion criteria were: (a) first recurrence of epithelial ovarian cancer; (b) platinum-free interval of ≥6 months; (c) intent to perform secondary cytoreductive surgery with complete macroscopic resection; and (d) WB-DWI/MRI was performed.Diagnostic tests of WB-DWI/MRI for predicting complete resection during secondary cytoreductive surgery are calculated as well as the progression-free and overall survival of the patients with a WB-DWI/MRI scan that showed resectable disease or not.In total, 238 patients could be identified, of whom 123 (51.7%) underwent secondary cytoreductive surgery. WB-DWI/MRI predicted resectable disease with a sensitivity of 93.6% (95% confidence interval [CI] 87.3% to 96.9%), specificity of 93.0% (95% CI 87.3% to 96.3%), and an accuracy of 93.3% (95% CI 89.3% to 96.1%). The positive predictive value was 91.9% (95% CI 85.3% to 95.7%).Prediction of resectable disease by WB-DWI/MRI correlated with improved progression-free survival (median 19 months vs 9 months; hazard ratio [HR] for progression 0.36; 95% CI 0.26 to 0.50) and overall survival (median 75 months vs 28 months; HR for death 0.33; 95% CI 0.23 to 0.47).WB-DWI/MRI accurately predicts resectable disease in patients with a platinum-free interval of ≥6 months at the time of secondary cytoreductive surgery and could be of complementary value to the currently used models.© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.